{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Intratumoral+Injection&page=2", "query": { "condition": "Intratumoral Injection", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Intratumoral+Injection&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T02:10:15.508Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04673942", "title": "A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Cancer", "Neoplasms", "Sarcoma", "Sarcoma,Soft Tissue", "Chondrosarcoma" ], "interventions": [ { "name": "AdAPT-001", "type": "BIOLOGICAL" }, { "name": "Checkpoint Inhibitor, Immune", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "EpicentRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2021-03-29", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2024-10-26", "last_synced_at": "2026-05-22T02:10:15.508Z", "location_count": 6, "location_summary": "Duarte, California • San Marcos, California • Santa Monica, California + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Marcos", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04673942" }, { "nct_id": "NCT06284590", "title": "Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma Stage III", "Melanoma Stage IV" ], "interventions": [ { "name": "L19IL2", "type": "DRUG" }, { "name": "L19TNF", "type": "DRUG" }, { "name": "L19IL2/L19TNF", "type": "DRUG" }, { "name": "KEYTRUDA®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Philogen S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2024-07-12", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2024-10-26", "last_synced_at": "2026-05-22T02:10:15.508Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06284590" }, { "nct_id": "NCT02927964", "title": "TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3a Follicular Lymphoma", "Recurrent Follicular Lymphoma", "Refractory Follicular Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "TLR9 Agonist SD-101", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Robert Lowsky", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2016-11-07", "completion_date": "2023-05-18", "has_results": true, "last_update_posted_date": "2024-10-16", "last_synced_at": "2026-05-22T02:10:15.508Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02927964" }, { "nct_id": "NCT03831295", "title": "SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Extracranial Solid Neoplasm", "Metastatic Malignant Solid Neoplasm" ], "interventions": [ { "name": "Anti-OX40 Antibody BMS 986178", "type": "BIOLOGICAL" }, { "name": "TLR9 Agonist SD-101", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Ronald Levy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2019-03-13", "completion_date": "2021-10-04", "has_results": false, "last_update_posted_date": "2023-11-22", "last_synced_at": "2026-05-22T02:10:15.508Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03831295" }, { "nct_id": "NCT06747390", "title": "Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Oropharyngeal Squamous Cell Carcinoma (OPSCCA)", "Oropharyngeal Cancer", "Human Papilloma Virus", "Squamous Cell Carcinoma" ], "interventions": [ { "name": "Lidocaine 1% Injectable Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ryan Carey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-04-23", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-05-22T02:10:15.508Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06747390" }, { "nct_id": "NCT03638765", "title": "Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Metastases", "Lung Cancer Metastatic", "Breast Cancer Metastatic" ], "interventions": [ { "name": "DCVax-Direct", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Northwest Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 24, "start_date": "2018-11", "completion_date": "2020-12", "has_results": false, "last_update_posted_date": "2018-08-20", "last_synced_at": "2026-05-22T02:10:15.508Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03638765" }, { "nct_id": "NCT05483868", "title": "A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-muscle-invasive Bladder Cancer", "NMIBC", "Non-Muscle Invasive Bladder Carcinoma", "Non-Muscle Invasive Bladder Neoplasms", "Non-Muscle Invasive Bladder Urothelial Carcinoma", "Urothelial Carcinoma Bladder" ], "interventions": [ { "name": "AU-011", "type": "DRUG" }, { "name": "AU-011 in Combination with Medical Laser Adminstration", "type": "COMBINATION_PRODUCT" }, { "name": "AU-011 in Combination with Medical Laser Administration", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Aura Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2022-09-26", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-05-22T02:10:15.508Z", "location_count": 11, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Santa Monica, California + 6 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "The Bronx", "state": "New York" }, { "city": "Myrtle Beach", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05483868" }, { "nct_id": "NCT00554372", "title": "A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Jennerex Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2008-08", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2016-02-04", "last_synced_at": "2026-05-22T02:10:15.508Z", "location_count": 5, "location_summary": "La Jolla, California • Rochester, Minnesota • Billings, Montana + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Billings", "state": "Montana" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00554372" }, { "nct_id": "NCT06177964", "title": "Lerapolturev (PVSRIPO) in GBM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Supratentorial Glioblastoma" ], "interventions": [ { "name": "Lerapolturev", "type": "DRUG" }, { "name": "Lomustine Pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Darell Bigner", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2024-07-15", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-05-22T02:10:15.508Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06177964" }, { "nct_id": "NCT03172936", "title": "Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors and Lymphomas" ], "interventions": [ { "name": "MIW815", "type": "DRUG" }, { "name": "PDR001", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2017-09-08", "completion_date": "2020-12-18", "has_results": false, "last_update_posted_date": "2022-05-03", "last_synced_at": "2026-05-22T02:10:15.508Z", "location_count": 4, "location_summary": "Los Angeles, California • Chicago, Illinois • Houston, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03172936" } ] }